Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.

Inclusion Criteria: * Age \>/= 19 years of age * Ability to provide informed consent before any trial-related activities * Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa meeting all of the following: 1. Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m/656 feet/2 blocks) for at least 90 days prior to the day of screening based on patient interview. 2. Ankle-brachial-index (ABI) equal to or below 0.90 (the leg with lowest index is chosen in case of bilateral disease) or ≥ 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, or a history of lower extremity revascularization Exclusion Criteria: * Current or previous treatment with any immunomodulating agent within 90 days prior to the day of screening. * Walking ability limited by conditions other than PAD * Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability). * Vascular revascularisation procedure for PAD of any kind 180 days prior to the day of screening. * Planned arterial revascularisation known on the day of screening. * Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack within 180 days prior to the day of screening. * Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV. * Signs/symptoms of critical limb ischemia (leg gangrene, rest pain, ischemic wounds, etc)